Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.39 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.31 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782868 | 1.00 | MAPT (0.39) | MAPTTRPA1DDAH1GAPDHPTPN1 | |
| SCHEMBL1783836 | 0.88 | GAPDH (0.33) | MAPTTRPA1DDAH1GAPDH | |
| SCHEMBL1783837 | 0.88 | GAPDH (0.33) | MAPTTRPA1DDAH1GAPDH | |
| SCHEMBL1782994 | 0.82 | MAPT (0.53) | MAPTTRPA1DDAH1GAPDHACHE | |
| SCHEMBL1782993 | 0.82 | MAPT (0.53) | MAPTTRPA1DDAH1GAPDHACHE | |
| SCHEMBL1783820 | 0.81 | MAPT (0.61) | MAPTTRPA1DDAH1GAPDHACHE | |
| SCHEMBL1783817 | 0.81 | MAPT (0.61) | MAPTTRPA1DDAH1GAPDHACHE | |
| SCHEMBL1784379 | 0.79 | MAPT (0.59) | MAPTTRPA1DDAH1GAPDHLTB4R2 | |
| SCHEMBL1784378 | 0.79 | MAPT (0.59) | MAPTTRPA1DDAH1GAPDHLTB4R2 | |
| SCHEMBL1781518 | 0.78 | GAPDH (0.42) | MAPTTRPA1DDAH1GAPDHACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | MAPT 906/4885TRPA1 1/4885DDAH1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.